Overview

Venetoclax is a BCL-2 selective inhibitor used in chronic lymphocytic leukemia and certain lymphomas, particularly after disease has escaped covalent BTK-inhibitor therapy. The resistance premise is that CLL cells overexpress BCL-2 to avoid programmed death, and blocking that anti-apoptotic protein reopens the death pathway even when kinase-directed treatment has failed. The 100 mg tablet from Tlph, Everest, and AbbVie, supplied in 112-tablet packs, supports the structured ramp-up schedule. Its activity after kinase-directed failure makes it a cornerstone of sequenced CLL care where continuing the same pathway would no longer help.

How It Works

Venetoclax binds the BH3 hydrophobic groove of BCL-2, displacing pro-apoptotic proteins such as BIM that were previously sequestered. Once freed, these proteins activate Bax and Bak, triggering mitochondrial outer-membrane permeabilization and cell death. Because this axis sits downstream of BTK signaling, tumors that acquired BTK-inhibitor resistance through mutation or bypass pathways remain vulnerable to BCL-2 blockade. Restoring apoptosis also undermines clonal subpopulations that survive BTK inhibition through parallel survival signals, deepening response.

Indications

Venetoclax is combined with anti-CD20 antibodies in CLL, including patients with del(17p) or TP53 mutation and those who progressed on a BTK inhibitor. It is also used in acute myeloid leukemia in defined regimens. Selection considers prior line count, fitness, and tumor lysis risk at start. Fit patients cleared for intensive combination and those needing oral therapy both fall within the BCL-2 directed population when criteria are met.

Dosage & Administration

Therapy begins with a 5-week ramp from 20 mg upward to 400 mg daily to limit tumor-lysis syndrome, using the 100 mg tablets alongside lower strengths. The 112-tablet pack supports later maintenance phases. Weekly step-ups follow lab and clinical monitoring mandated by the prescribing protocol and documented at each visit.

Storage & Sourcing

Store Venetoclax below 30°C in the original container, protected from moisture. As an oral targeted agent it ships without cold-chain, aiding cross-border supply. Confirm batch, expiry, and serialization on receipt to support compliance and traceability. Ambient-stable tablets and structured dosing packs support the prolonged outpatient courses that define maintenance phases.

FAQ

Q: Which CLL populations receive Venetoclax after BTK-inhibitor failure? A: Patients who progressed on ibrutinib or acalabrutinib, including high-risk del(17p) or TP53-mutated disease, are key candidates for BCL-2 based combination.

Q: Why is Venetoclax ramp-up required in resistance settings? A: Gradual dose escalation controls the surge of tumor-cell death and reduces serious tumor-lysis syndrome during the vulnerable early weeks.

Q: How is tumour-lysis risk managed with BCL-2 therapy? A: Baseline hydration, close lab monitoring, and the mandated weekly dose ramp plus hospitalization criteria for high-burden disease manage the risk.